Navigation Links
Hair-growth drug artificially lowers PSA levels in prostate cancer screening, study finds

The popular hair-growth drug finasteride, taken by millions of balding men, artificially lowers the results of the prostate-specific antigen (PSA) test, the standard screening test for prostate cancer, a multicenter study has found.

The study, involving 308 men ranging in age from 40 to 60 years old, is available online in the British medical journal The Lancet and is scheduled to be published after Jan. 1, 2007. The study calls for new clinical guidelines for primary-care physicians, dermatologists and urologists to account for the role of finasteride, known as Propecia when used for hair loss, while evaluating PSA results.

"It's not universally known that finasteride lowers PSA levels in younger men who take it for hair growth," said Dr. Claus Roehrborn, chairman of urology at UT Southwestern Medical Center and co-principal investigator of The Lancet study, along with Dr. Anthony D'Amico of Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston. "It is important for physicians to know that many young men take Propecia and that their PSA level is lowered artificially. Doctors need to adjust the PSA interpretation by multiplying it times two for these men."

Finasteride was initially developed in the 1990s for the treatment of benign prostatic hyperplasia (BPH), better known as enlarged-prostate disease, and was first approved by the U.S. Food and Drug Administration for this use. Patients with BPH must strain to pass urine and feel the urge to urinate frequently. BPH can lead to the inability to urinate and urinary tract infection.

In 1997 the FDA approved finasteride for the treatment of male-pattern baldness. While Propecia is administered at 1 milligram per day, patients who take the finasteride drug Proscar for BPH get a five times higher dosage, 5 mg per day. "The impact of finasteride on PSA levels is significant," said Dr. Roehrborn. "This needs to be realized by all internists, family-care doctors, dermato
'"/>

Source:UT Southwestern Medical Center


Page: 1 2

Related biology news :

1. Stimulation of the semicircular canals can artificially control human walking and balance
2. Bacteria could make new library of cancer drugs that are too complex to create artificially
3. Medical whistleblowers speak out
4. Bumblebees copy one another when contending with unfamiliar flowers
5. Reducing antibiotic use lowers rates of drug-resistant bacteria
6. Recreating Flowers for Algernon with a happy ending
7. AIDS drug from sunflowers
8. How nice, brown rice: Study shows rice bran lowers blood pressure in rats
9. Wild bees and the flowers they pollinate are disappearing together
10. Genetic snooze button governs timing of spring flowers
11. How did bilaterally symmetric flowers evolve from radially symmetric ones?
Post Your Comments:
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
(Date:2/5/2015)... Calif. , Jan. 30, 2015  It is ... great power and potential for genomic science as a ... in disease prevention and treatment.  I was honored to ... new, government-funded precision medicine program. Since ... the science of genomics—from the first sequenced genome of ...
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2
... Engineering (NCE) at NJIT has been selected by the National ... and colleges across the nation in a new five-year program ... selection is the culmination of a two-year long effort led ... Currently, some 43 percent of engineering undergraduates switch ...
... Loud noise, especially repeated loud noise, is known ... the cochlea and eventually lead to deafness. In mammals ... able to re-grow the damaged hair cells and restore ... journal BMC Neuroscience shows that growth hormone ...
... Quest Diagnostics Incorporated (NYSE: DGX ), the ... today issued its annual report on U.S. worker drug ... includes its first state-by-state analysis of methamphetamine positives, based ... the general U.S. workforce from January-December 2010, revealing that ...
Cached Biology News:NSF funds NJIT's participation in program to retain engineering students 2Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 2Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 3Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 4Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™ 5
(Date:2/27/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... today announced that it will be presenting at CALBIO ... 2 nd at 3pm PST. Patrick Lucy, chief business ... the current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and ...
(Date:2/26/2015)... , Feb. 26, 2015 S&P Capital ... Factual Stock Report coverage on MabVax Therapeutics Holdings Inc ... is a clinical stage biotechnology company focused on the ... medical needs in the treatment of cancer. MabVax has ... on the protective immune responses generated by patients who ...
(Date:2/26/2015)... Calif. , Feb. 26, 2015   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and Chief Executive Officer of ... and Company 35 th Annual Healthcare Conference on ... conference is being held at the Boston Marriott Copley ...
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, Inc. ... products for skin and hair rejuvenation, has announced ... agency of record for investor relations and strategic ... our distribution, sales and diversification strategies – and ... and prospective shareholders," stated Ali Kharazmi CEO of ...
Breaking Biology Technology:S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3
... - Oncolytics Biotech Inc.,(TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the ... ended December 31, 2007., "2007 was our ... of the Company,s clinical trial program for REOLYSIN(R) ... being expanded and,initiated," said Dr. Brad Thompson, President ...
... March 6 VWR Funding, Inc., the,parent company of VWR International, LLC, a leading global ... and year-end financial results., Who: ... Jack L. Wyszomierski, Executive Vice-President & Chief ... Financial Officer, When: Wednesday, March 12, ...
... on Clinical Developments, MONTREAL, March 6 /PRNewswire-FirstCall/ - ... findings from the,third cohort in its Phase II trial ... the compiled data from a,total of 18 patients showed ... at weeks 4, 6 and 8, and of the ...
Cached Biology Technology:Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 2Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 3Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 4Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 5Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 6Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 7Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 8Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007 9VWR Funding, Inc. to Hold Fourth Quarter and Year-End 2007 Financial Results Conference Call 2ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia 2ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia 3
Contains 0.2 g/L EDTA4Na in phosphate-buffered saline....
Quantibody Human Angiogenesis Array 1 (1 slide) Class: Quantitative Antibody Arrays Product Group: Antibody Array...
BD IMagnet 1 each...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
Biology Products: